123 related articles for article (PubMed ID: 37425844)
1. Glutamine antagonist DRP-104 suppresses tumor growth and enhances response to checkpoint blockade in
Pillai R; LeBoeuf SE; Hao Y; New C; Blum JLE; Rashidfarrokhi A; Huang SM; Bahamon C; Wu WL; Karadal-Ferrena B; Herrera A; Ivanova E; Cross M; Bossowski JP; Ding H; Hayashi M; Rajalingam S; Karakousi T; Sayin VI; Khanna KM; Wong KK; Wild R; Tsirigos A; Poirier JT; Rudin CM; Davidson SM; Koralov SB; Papagiannakopoulos T
bioRxiv; 2023 Jun; ():. PubMed ID: 37425844
[TBL] [Abstract][Full Text] [Related]
2. Glutamine antagonist DRP-104 suppresses tumor growth and enhances response to checkpoint blockade in
Pillai R; LeBoeuf SE; Hao Y; New C; Blum JLE; Rashidfarrokhi A; Huang SM; Bahamon C; Wu WL; Karadal-Ferrena B; Herrera A; Ivanova E; Cross M; Bossowski JP; Ding H; Hayashi M; Rajalingam S; Karakousi T; Sayin VI; Khanna KM; Wong KK; Wild R; Tsirigos A; Poirier JT; Rudin CM; Davidson SM; Koralov SB; Papagiannakopoulos T
Sci Adv; 2024 Mar; 10(13):eadm9859. PubMed ID: 38536921
[TBL] [Abstract][Full Text] [Related]
3. LKB1 and KEAP1/NRF2 Pathways Cooperatively Promote Metabolic Reprogramming with Enhanced Glutamine Dependence in
Galan-Cobo A; Sitthideatphaiboon P; Qu X; Poteete A; Pisegna MA; Tong P; Chen PH; Boroughs LK; Rodriguez MLM; Zhang W; Parlati F; Wang J; Gandhi V; Skoulidis F; DeBerardinis RJ; Minna JD; Heymach JV
Cancer Res; 2019 Jul; 79(13):3251-3267. PubMed ID: 31040157
[TBL] [Abstract][Full Text] [Related]
4. Sirpiglenastat (DRP-104) Induces Antitumor Efficacy through Direct, Broad Antagonism of Glutamine Metabolism and Stimulation of the Innate and Adaptive Immune Systems.
Yokoyama Y; Estok TM; Wild R
Mol Cancer Ther; 2022 Oct; 21(10):1561-1572. PubMed ID: 35930753
[TBL] [Abstract][Full Text] [Related]
5. Discovery of DRP-104, a tumor-targeted metabolic inhibitor prodrug.
Rais R; Lemberg KM; Tenora L; Arwood ML; Pal A; Alt J; Wu Y; Lam J; Aguilar JMH; Zhao L; Peters DE; Tallon C; Pandey R; Thomas AG; Dash RP; Seiwert T; Majer P; Leone RD; Powell JD; Slusher BS
Sci Adv; 2022 Nov; 8(46):eabq5925. PubMed ID: 36383674
[TBL] [Abstract][Full Text] [Related]
6. Targeting glutamine dependence with DRP-104 inhibits proliferation and tumor growth of castration-resistant prostate cancer.
Moon D; Hauck JS; Jiang X; Quang H; Xu L; Zhang F; Gao X; Wild R; Everitt JI; Macias E; He Y; Huang J
Prostate; 2024 Mar; 84(4):349-357. PubMed ID: 38084059
[TBL] [Abstract][Full Text] [Related]
7. KEAP1 mutation in lung adenocarcinoma promotes immune evasion and immunotherapy resistance.
Zavitsanou AM; Pillai R; Hao Y; Wu WL; Bartnicki E; Karakousi T; Rajalingam S; Herrera A; Karatza A; Rashidfarrokhi A; Solis S; Ciampricotti M; Yeaton AH; Ivanova E; Wohlhieter CA; Buus TB; Hayashi M; Karadal-Ferrena B; Pass HI; Poirier JT; Rudin CM; Wong KK; Moreira AL; Khanna KM; Tsirigos A; Papagiannakopoulos T; Koralov SB
Cell Rep; 2023 Nov; 42(11):113295. PubMed ID: 37889752
[TBL] [Abstract][Full Text] [Related]
8. The discovery and characterization of K-563, a novel inhibitor of the Keap1/Nrf2 pathway produced by Streptomyces sp.
Hori R; Yamaguchi K; Sato H; Watanabe M; Tsutsumi K; Iwamoto S; Abe M; Onodera H; Nakamura S; Nakai R
Cancer Med; 2019 Mar; 8(3):1157-1168. PubMed ID: 30735010
[TBL] [Abstract][Full Text] [Related]
9. Glutamine antagonists may KEAP lung cancer in check.
Blatt EB; DeBerardinis RJ
Sci Adv; 2024 Mar; 10(13):eado7808. PubMed ID: 38536918
[TBL] [Abstract][Full Text] [Related]
10. Keap1 loss promotes Kras-driven lung cancer and results in dependence on glutaminolysis.
Romero R; Sayin VI; Davidson SM; Bauer MR; Singh SX; LeBoeuf SE; Karakousi TR; Ellis DC; Bhutkar A; Sánchez-Rivera FJ; Subbaraj L; Martinez B; Bronson RT; Prigge JR; Schmidt EE; Thomas CJ; Goparaju C; Davies A; Dolgalev I; Heguy A; Allaj V; Poirier JT; Moreira AL; Rudin CM; Pass HI; Vander Heiden MG; Jacks T; Papagiannakopoulos T
Nat Med; 2017 Nov; 23(11):1362-1368. PubMed ID: 28967920
[TBL] [Abstract][Full Text] [Related]
11. NFE2L2/KEAP1 Mutations Correlate with Higher Tumor Mutational Burden Value/PD-L1 Expression and Potentiate Improved Clinical Outcome with Immunotherapy.
Xu X; Yang Y; Liu X; Cao N; Zhang P; Zhao S; Chen D; Li L; He Y; Dong X; Wang K; Lin H; Mao N; Liu L
Oncologist; 2020 Jun; 25(6):e955-e963. PubMed ID: 32272498
[TBL] [Abstract][Full Text] [Related]
12. Glutaminase inhibition impairs CD8 T cell activation in STK11-/Lkb1-deficient lung cancer.
Best SA; Gubser PM; Sethumadhavan S; Kersbergen A; Negrón Abril YL; Goldford J; Sellers K; Abeysekera W; Garnham AL; McDonald JA; Weeden CE; Anderson D; Pirman D; Roddy TP; Creek DJ; Kallies A; Kingsbury G; Sutherland KD
Cell Metab; 2022 Jun; 34(6):874-887.e6. PubMed ID: 35504291
[TBL] [Abstract][Full Text] [Related]
13. Loss-of-function mutations in KEAP1 drive lung cancer progression via KEAP1/NRF2 pathway activation.
Gong M; Li Y; Ye X; Zhang L; Wang Z; Xu X; Shen Y; Zheng C
Cell Commun Signal; 2020 Jun; 18(1):98. PubMed ID: 32576270
[TBL] [Abstract][Full Text] [Related]
14.
Occhiuto CJ; Liby KT
Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542481
[TBL] [Abstract][Full Text] [Related]
15. Metabolic barriers in non-small cell lung cancer with
Tanaka I; Koyama J; Itoigawa H; Hayai S; Morise M
Front Oncol; 2023; 13():1249237. PubMed ID: 37675220
[TBL] [Abstract][Full Text] [Related]
16. A clinical drug library screen identifies clobetasol propionate as an NRF2 inhibitor with potential therapeutic efficacy in KEAP1 mutant lung cancer.
Choi EJ; Jung BJ; Lee SH; Yoo HS; Shin EA; Ko HJ; Chang S; Kim SY; Jeon SM
Oncogene; 2017 Sep; 36(37):5285-5295. PubMed ID: 28504720
[TBL] [Abstract][Full Text] [Related]
17. ERBB3 and IGF1R Signaling Are Required for Nrf2-Dependent Growth in KEAP1-Mutant Lung Cancer.
Vartanian S; Lee J; Klijn C; Gnad F; Bagniewska M; Schaefer G; Zhang D; Tan J; Watson SA; Liu L; Chen H; Liang Y; Watanabe C; Cuellar T; Kan D; Hartmaier RJ; Lau T; Costa MR; Martin SE; Merchant M; Haley B; Stokoe D
Cancer Res; 2019 Oct; 79(19):4828-4839. PubMed ID: 31416841
[TBL] [Abstract][Full Text] [Related]
18. TOX promotes the exhaustion of antitumor CD8
Wang X; He Q; Shen H; Xia A; Tian W; Yu W; Sun B
J Hepatol; 2019 Oct; 71(4):731-741. PubMed ID: 31173813
[TBL] [Abstract][Full Text] [Related]
19. Loss of Keap1 function activates Nrf2 and provides advantages for lung cancer cell growth.
Ohta T; Iijima K; Miyamoto M; Nakahara I; Tanaka H; Ohtsuji M; Suzuki T; Kobayashi A; Yokota J; Sakiyama T; Shibata T; Yamamoto M; Hirohashi S
Cancer Res; 2008 Mar; 68(5):1303-9. PubMed ID: 18316592
[TBL] [Abstract][Full Text] [Related]
20. Clinicopathological, microenvironmental and genetic determinants of molecular subtypes in KEAP1/NRF2-mutant lung cancer.
Cai MC; Chen M; Ma P; Wu J; Lu H; Zhang S; Liu J; Zhao X; Zhuang G; Yu Z; Fu Y
Int J Cancer; 2019 Feb; 144(4):788-801. PubMed ID: 30411339
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
